Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

rch and development 8,161 4,470 20,390 17,640

General and administrative 1,351 680 4,209 1,986

Total operating expenses 9,512 5,150 24,599 19,626

Loss from operations (7,049) (2,687) (17,211) (12,238)

Other income (expense)

Interest income 504 259 1,699 732

Interest expense (193) (279) (647) (735)

Other income (expense), net (36) - 946 2

Total other income (expense) 275 (20) 1,998 (1)

Net loss (6,774) (2,707) (15,213) (12,239)

Dividends and accretion

to redemption value of

redeemable convertible

preferred stock - (1,237) - (3,534)

Net loss attributable

to common stockholders $(6,774) $(3,944) $(15,213) $(15,773)

Basic and diluted net

loss per share

attributable to common

stockholders* $(0.43) $(7.18) $(0.97) $(29.19)

Weighted average shares

used in the computation

of basic and diluted net

loss per share

attributable to

common stockholders *15,733,970 549,481 15,711,212 540,395

* Basic and diluted net loss per share attributable to common

stockholders and weighted average shares outstanding were impacted by

the conversion of preferred stock and issuance of common stock in

connection with the Axonyx merger.


'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 Pacific ... 2014 Summary Global Markets Direct,s, ,Pacific ... 2014, provides an overview of the Pacific Northwest ... This report provides comprehensive information on the current ... complete with comparative analysis at various stages, therapeutics ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Shimadzu ... extensometer, an easy-to-use and highly precise tool for ... with considerable elongation. With 1000-mm maximum movement distance, ... percent for a gauge length of 10 mm. ... measurement accuracy above 50-mm stroke and within +/- ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Over the ... primarily due to rising R&D budgets and increased acceptance ... fast growing pharmaceutical and biotechnology industries are also catalyzing ... laboratory filtration market is expected to grow at a ... is estimated to be worth $2,532.6 million by 2019. ...
(Date:9/30/2014)... 30, 2014 Follow us on ... each type of cholesterol carrier or lipoprotein in the ... excessive cholesterol levels in the body, especially along the ... heart attack and other cardiovascular disorders. Cardiovascular Diseases (CVD) ... for cholesterol levels on a regular basis, to assess ...
Breaking Biology Technology:Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4
... Expands Decision Resources, Inc.,s Portfolio to Include Global ... Physician and Consumer Digital Market Research, ... Inc., one of the world,s leading research and advisory ... it,acquired Manhattan Research, a leading provider of access to ...
... AVIV, Israel, June 17 BSP Ltd.,( http://www.bsp.co.il/pressall.asp ... for non-invasive diagnosis and monitoring of Ischemic Heart,Disease, ... a private,funding round, that included existing shareholders in ... developed the HyperQ(TM), a cutting-edge technology that offers,highly ...
... and fast PCR amplification ... in a fully portable ... a leading,developer of state-of-the-art PCR devices and Cell-based assay systems,today ... San,Diego Convention Center that it has successfully completed development of,Palm ...
Cached Biology Technology:Decision Resources, Inc. Acquires Manhattan Research 2Decision Resources, Inc. Acquires Manhattan Research 3BSP Raises $2.6 Million Dollars From Private Investors 2Ahram Biosystems Completes Development of a Palm-Size Portable PCR Device 2
(Date:9/30/2014)... . FRANKFURT. Truffles, ... the world. Because they grow underground, people use trained dogs ... truffles is not only of interest to gourmets. A group ... Goethe University Frankfurt have discovered that the smell of white ... inside truffle fruiting bodies. , White truffles from the Piedmont ...
(Date:9/30/2014)... that a new class of chemical compounds makes ... have also pinpointed the relevant target enzyme, thus ... , Researchers led by LMU,s Professor Angelika Vollmar ... Mnchen have identified a class of chemicals that ... against malignant tumors. The compound is itself non-toxic, ...
(Date:9/30/2014)... available in German . ... response to risky situations such as exposure to predators. ... found in a long-term study on different populations of ... rate and ambient temperature. High metabolic rates and low ... these scenarios birds were more likely to approach potential ...
Breaking Biology News(10 mins):On the trail of the truffle flavor 2Cancer therapy: Driving cancer cells to suicide 2Risky metabolism 2
... As the 2010 United Nations International Year of ... (MBG) and the Royal Botanic Gardens, Kew (RBG Kew) ... international resource is a working list of all land ... diversity and effective conservation of plants. The completion of ...
... In a recent issue of HortTechnology , Purdue ... on a study of the effects of a technique called ... are commonly applied as sprays or media drenches, bulb crops ... The experiments were designed to determine if dipping Easter lily ...
... Dec. 29, 2010 Patients with diabetes, kidney disease and ... have a higher risk of cardiovascular disease or death, researchers ... results suggest that testing such patients, responsiveness to the drug ... their risk, said Dr. Robert Toto, professor of internal medicine ...
Cached Biology News:Kew Gardens and Missouri Botanical Garden announce the completion of the Plant List 2Kew Gardens and Missouri Botanical Garden announce the completion of the Plant List 3Bulb dipping controls Easter lily growth 2Poor response to anti-anemia drug predicts higher risk of heart disease or death 2Poor response to anti-anemia drug predicts higher risk of heart disease or death 3
Rabbit polyclonal to Synapsin II ( Abpromise for all tested applications). entrezGeneID: 6854 SwissProtID: Q92777...
... designed for sequencing inserts cloned into M13/pUC-based ... T3 RNA polymerase promoters, or lambda gt10 ... a concentration of 0.1 µg/µl in water. ... sequencing reactions using SequiTherm™ EXCEL™ II DNA ...
... Expression is a powerful application ... Utilising a novel interface, Expression makes ... incredibly simple. Expression uses the very ... standards in the way sequences are ...
... with AutoGen AutoGenesys, BioRobotics BioPick, BioGrid, TAS ... picking systems This CLS number is a ... Cornings product number. If showing no availability ... number (D9314) or contact customer service for ...
Biology Products: